GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Huadong Medicine Co Ltd (SZSE:000963) » Definitions » ROE % Adjusted to Book Value

Huadong Medicine Co (SZSE:000963) ROE % Adjusted to Book Value : 6.47% (As of Mar. 2024)


View and export this data going back to 2000. Start your Free Trial

What is Huadong Medicine Co ROE % Adjusted to Book Value?

Huadong Medicine Co's ROE % for the quarter that ended in Mar. 2024 was 16.04%. Huadong Medicine Co's PB Ratio for the quarter that ended in Mar. 2024 was 2.48. Huadong Medicine Co's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2024 was 6.47%.


Huadong Medicine Co ROE % Adjusted to Book Value Historical Data

The historical data trend for Huadong Medicine Co's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Huadong Medicine Co ROE % Adjusted to Book Value Chart

Huadong Medicine Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.29 6.58 3.48 3.22 4.14

Huadong Medicine Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.79 3.59 4.16 3.63 6.47

Competitive Comparison of Huadong Medicine Co's ROE % Adjusted to Book Value

For the Drug Manufacturers - Specialty & Generic subindustry, Huadong Medicine Co's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Huadong Medicine Co's ROE % Adjusted to Book Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Huadong Medicine Co's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Huadong Medicine Co's ROE % Adjusted to Book Value falls into.



Huadong Medicine Co ROE % Adjusted to Book Value Calculation

Huadong Medicine Co's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=14.33% / 3.46
=4.14%

Huadong Medicine Co's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=16.04% / 2.48
=6.47%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Huadong Medicine Co ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Huadong Medicine Co's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Huadong Medicine Co (SZSE:000963) Business Description

Traded in Other Exchanges
N/A
Address
468 Yan’an Road, Floor 7, 9 and 10, Gate No. 1, Building No. 1, Hangzhou, CHN, 310006
Huadong Medicine Co Ltd is engaged in the production and sales of antibiotics, proprietary Chinese medicine, chemical synthetic medicine and genetic engineering drugs products. It is also engaged in the wholesale, retail and distribution business of Chinese and western medicine, Chinese herbal medicine, medical apparatus, and instruments. The main business of the company is divided into pharmaceutical business sales and the industry of pharmaceutical. The product portfolio of the company includes Corbrin capsule, Cymusi, New Cyspin, Kasiping, Panlisu, Acarbose, and others.
Executives
He Ru Fen Supervisors
Hu Bao Zhen Supervisors
Zhou Shun Hua Executives
Shao Ling Min Supervisors
Wan Ling Ling Executives
Fu Hang Director
Yue Jin Director
Chen Bo Secretary Dong
Qin Yun Supervisors
Li Bang Liang Directors, executives
Zhou Jin Bao Directors, executives

Huadong Medicine Co (SZSE:000963) Headlines

No Headlines